ABBVIE INC CEDEAR EACH 10 REPR 1 COMABBVIE INC CEDEAR EACH 10 REPR 1 COMABBVIE INC CEDEAR EACH 10 REPR 1 COM

ABBVIE INC CEDEAR EACH 10 REPR 1 COM

No trades
See on Supercharts

Key facts today


Rothschild & Co Redburn has adjusted AbbVie's price target to $240 from $239 while maintaining a Buy rating.
AbbVie shares rose 0.3% to 0.6% in premarket trading, joining other major pharma firms after President Trump's remarks on possible tariffs in the sector.
Analyze the impactAnalyze the impact
Market capitalization
‪415.18 T‬ARS
2,250ARS
‪3.88 T‬ARS
‪51.58 T‬ARS
Beta (1Y)
0.04

About AbbVie Inc.


CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
ARBCOM4603M9
FIGI
BBG00ZL7CCS3
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Check out other big names from the same industry as ABBV.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
7.83%
Maturity date
Mar 15, 2045
A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
7.77%
Maturity date
Jun 15, 2044
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
7.48%
Maturity date
Oct 1, 2042
XS190919331
ALLERGAN FNDG 18/28
Yield to maturity
6.97%
Maturity date
Nov 15, 2028
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
6.38%
Maturity date
Mar 15, 2035
4ABI
ABBVIE 20/49
Yield to maturity
6.32%
Maturity date
Nov 21, 2049
US287YAW9
ABBVIE 16/46
Yield to maturity
6.20%
Maturity date
May 14, 2046
4ABF
ABBVIE 18/48
Yield to maturity
6.06%
Maturity date
Nov 14, 2048
US287YAM1
ABBVIE 2042
Yield to maturity
6.06%
Maturity date
Nov 6, 2042
4ABB
ABBVIE 15/45
Yield to maturity
6.06%
Maturity date
May 14, 2045
US287YDX4
ABBVIE 24/64
Yield to maturity
6.01%
Maturity date
Mar 15, 2064

See all ABBV bonds